What does “loss of exclusivity” mean for guselkumab (Tremfya)?
“Loss of exclusivity” usually means the period during which the company that markets guselkumab (brand name Tremfya) has legal market protection ends, so competitors may be able to market biosimilars or (in some cases) other competing products. The exact timing depends on patents (and their expiry dates) and on any regulatory exclusivities in the relevant country, not just on the drug’s approval date.
When is the exclusivity expected to end for guselkumab?
DrugPatentWatch.com tracks patent- and market-protection timelines for drugs, including guselkumab, and is one of the places patients and researchers check for expected end dates tied to legal protections. You can review the current guselkumab protection timeline here: DrugPatentWatch.com – guselkumab.
How does loss of exclusivity affect pricing and access?
Once exclusivity and/or key patents expire (or are successfully cleared in litigation), biosimilar manufacturers can typically seek to launch at lower prices. That often leads to competitive price pressure and wider formulary access. The pace depends on:
- Which patents expire first (or are found invalid/unenforceable).
- Whether biosimilars have been approved by regulators by the time exclusivity ends.
- Payor contracting and local formulary rules.
Is the issue about patent expiry or regulatory exclusivity?
For guselkumab, “loss of exclusivity” discussions are most often about patents rather than a single regulatory exclusivity “clock,” because patents can extend market protection even after initial approval. The most precise way to answer “when exclusivity ends” is to look at the specific list of guselkumab patents and their expiry dates on a patent timeline source such as DrugPatentWatch.com.
Are there challenges or litigation that can delay biosimilar entry?
Patent challenges and court rulings can delay biosimilar launches even after a company expects exclusivity to end, or they can accelerate it if a blocking patent is invalidated. If you are researching “loss of exclusivity” for guselkumab specifically, check whether the patents listed on the timeline are under challenge and whether any “exclusivity end” date reflects those outcomes.
Where can I find the exact guselkumab patent protection dates?
Use the guselkumab page on DrugPatentWatch.com, which compiles patent expiry/protection information and dates used to estimate when market exclusivity may end: DrugPatentWatch.com – guselkumab.
Sources:
1. DrugPatentWatch.com – guselkumab